Literature DB >> 25155425

The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass-pollen-induced allergic rhinoconjunctivitis.

P Devillier1, O Chassany, E Vicaut, O de Beaumont, B Robin, J F Dreyfus, P J Bousquet.   

Abstract

BACKGROUND: The minimally important difference (MID) has been defined as the smallest improvement considered worthwhile by a patient. The MID has not been estimated for the Rhinoconjunctivitis Total Symptom Score (RTSS).
METHODS: In a prospective multicentre study, patients consulting for grass-pollen-induced allergic rhinitis (AR) recorded a 15-point global rating of change scale (GRCS) score and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score on a weekly basis and the individual symptom scores comprising the RTSS on a daily basis over two consecutive weeks. The MID in the RTSS was determined with anchor-based methods (using the GRCS and the RQLQ) and a distribution-based method [based on the RTSS' standard deviation (SD)].
RESULTS: The study population comprised 806 patients (253 children, 250 adolescents and 303 adults). During the first week of the study, the mean ± SD RTSSs for these age groups were 6.5 ± 3.3, 6.8 ± 3.4 and 7.0 ± 3.4, respectively. For an improvement of 2 points in the GRCS or 0.5 points in the RQLQ score, the regression analysis yielded MIDs in the RTSS of 1.24 ± 0.17 and 1.12 ± 0.14 in children, 1.33 ± 0.14 and 1.20 ± 0.13 in adolescents and 1.13 ± 0.14 and 0.89 ± 0.12 in adults, respectively. When applying distribution-based methods, the MID ranged from 1.09 to 1.13 (based on 0.33 SDs of the first-week RTSS) and from 1.22 to 1.40 (based on 0.5 SDs of the difference in RTSSs between the first and second weeks).
CONCLUSION: The MID in the RTSS was consistently estimated as 1.1-1.3 (and could conceivably be rounded to 1) in patients with grass-pollen-induced AR.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allergic rhinoconjunctivitis; minimally important difference; symptom score

Mesh:

Substances:

Year:  2014        PMID: 25155425     DOI: 10.1111/all.12518

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

Review 1.  Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.

Authors:  Harold S Nelson; Moises A Calderon; David I Bernstein; Thomas B Casale; Stephen R Durham; Jens S Andersen; Robert Esch; Linda S Cox; Hendrik Nolte
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

2.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

3.  Minimal clinically important difference for the rhinoconjunctivitis quality of life questionnaire in allergic rhinitis in Thai population.

Authors:  Pongsakorn Tantilipikorn; Pennapha Saisombat; Pacharaporn Phonpornpaiboon; Bangon Pinkaew; Watcharee Lermankul; Chaweewan Bunnag
Journal:  Asia Pac Allergy       Date:  2019-01-22

4.  A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy.

Authors:  Massimo Bilancia; Giuseppe Pasculli; Danilo Di Bona
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

5.  Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis.

Authors:  Petra Zieglmayer; René Schmutz; Patrick Lemell; Nicole Unger-Manhart; Sabine Nakowitsch; Andreas Goessl; Markus Savli; René Zieglmayer; Eva Prieschl-Grassauer
Journal:  Clin Exp Allergy       Date:  2020-07-07       Impact factor: 5.018

6.  Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy.

Authors:  Michael S Blaiss; Ruta Gronskyte Juhl; Leonard Q C Siew; Eva Hammerby; Philippe Devillier
Journal:  Allergy       Date:  2022-01-22       Impact factor: 14.710

7.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Authors:  Petra Zieglmayer; Margarete Focke-Tejkl; René Schmutz; Patrick Lemell; René Zieglmayer; Milena Weber; Renata Kiss; Katharina Blatt; Peter Valent; Frank Stolz; Hans Huber; Angela Neubauer; Anette Knoll; Friedrich Horak; Rainer Henning; Rudolf Valenta
Journal:  EBioMedicine       Date:  2016-08-20       Impact factor: 8.143

Review 8.  MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence.

Authors:  J Bousquet; S Arnavielhe; A Bedbrook; M Bewick; D Laune; E Mathieu-Dupas; R Murray; G L Onorato; J L Pépin; R Picard; F Portejoie; E Costa; J Fonseca; O Lourenço; M Morais-Almeida; A Todo-Bom; A A Cruz; J da Silva; F S Serpa; M Illario; E Menditto; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; D Larenas-Linnemann; M Fuentes Perez; Y R Huerta Villabolos; D Rivero-Yeverino; E Rodriguez-Zagal; F Amat; I Annesi-Maesano; I Bosse; P Demoly; P Devillier; J F Fontaine; J Just; T P Kuna; B Samolinski; A Valiulis; R Emuzyte; V Kvedariene; D Ryan; A Sheikh; P Schmidt-Grendelmeier; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P Tomazic; W J Fokkens; N H Chavannes; S Reitsma; J M Anto; V Cardona; T Dedeu; J Mullol; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; B Gemicioğlu; A Yorgancioglu; N Papadopoulos; E P Prokopakis; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; E Zernotti; I Kull; E Melen; M Wickman; C Bachert; P Hellings; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; M Sova; G De Vries; M van Eerd; I Agache; T Casale; M Dykewickz; R N Naclerio; Y Okamoto; D V Wallace
Journal:  Clin Transl Allergy       Date:  2018-10-25       Impact factor: 5.871

9.  Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen.

Authors:  Lars Ahlbeck; Emelie Ahlberg; Janne Björkander; Caroline Aldén; Georgia Papapavlou; Laura Palmberg; Ulla Nyström; Pavlos Retsas; Patrik Nordenfelt; Totte Togö; Pål Johansen; Bo Rolander; Karel Duchén; Maria C Jenmalm
Journal:  Clin Exp Allergy       Date:  2022-04-01       Impact factor: 5.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.